The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

The present invention relates to a modified Slmyc2 gene, which may comprise at least one modification as compared to the wild type sequence of SEQ ID No. 5, which modification leads to the reduction or absence of SlMYC2 protein activity, wherein the modified Slmyc2 gene is capable of conferring an aberrant glandular hair phenotype to a Solanum lycopersicum plant. The modification may be suitably selected from a modification that decreases the mRNA level of the Slmyc2 gene, a modification that decreases the level of the SlMYC2 protein and/or a modification that decreases the activity of the SlMYC2 protein, as compared to the wild type Slmyc2 gene of SEQ ID No. 5.

The present invention relates to a modified Slmyc2 gene, which may comprise at least one modification as compared to the wild type sequence of SEQ ID No. 5, which modification leads to the reduction or absence of SlMYC2 protein activity, wherein the modified Slmyc2 gene is capable of conferring an aberrant glandular hair phenotype to a Solanum lycopersicum plant. The modification may be suitably selected from a modification that decreases the mRNA level of the Slmyc2 gene, a modification that decreases the level of the SlMYC2 protein and/or a modification that decreases the activity of the SlMYC2 protein, as compared to the wild type Slmyc2 gene of SEQ ID No. 5.

The present application belongs to the field of medicine. The present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity and the use thereof. The present application further relates to a pharmaceutical composition comprising the GLP-1 polypeptide. In particular, the present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity, or a pharmaceutically acceptable salt thereof, characterized in that the GLP-1 polypeptide has a mutation from threonine to proline at the position corresponding to the 13th position of the amino acid sequence of GLP-1.

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Synuclein-gamma (SNCG) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or endometrial lesion growth.

The present invention relates to a broken or kinked helical peptide or peptide analogue and the use thereof, and more particularly to a Gram-negative bacterial membrane-penetrating peptide or peptide analogue wherein an alpha-helical amphipathic peptide composed of hydrophobic amino acids and hydrophilic amino acids has a kinked structure, or an antimicrobial composition employing the specific activity of the peptide against the Gram-negative bacterial membrane, or an antimicrobial composition for co-administration, or a conjugate comprising a drug linked to the peptide or peptide analogue, or an antibiotic comprising the same.

The present invention relates to a modified Slmyc2 gene, which may comprise at least one modification as compared to the wild type sequence of SEQ ID No. 5, which modification leads to the reduction or absence of SlMYC2 protein activity, wherein the modified Slmyc2 gene is capable of conferring an aberrant glandular hair phenotype to a Solanum lycopersicum plant. The modification may be suitably selected from a modification that decreases the mRNA level of the Slmyc2 gene, a modification that decreases the level of the SlMYC2 protein and/or a modification that decreases the activity of the SlMYC2 protein, as compared to the wild type Slmyc2 gene of SEQ ID No. 5.

The present invention relates to a modified Slmyc2 gene, which may comprise at least one modification as compared to the wild type sequence of SEQ ID No. 5, which modification leads to the reduction or absence of SlMYC2 protein activity, wherein the modified Slmyc2 gene is capable of conferring an aberrant glandular hair phenotype to a Solanum lycopersicum plant. The modification may be suitably selected from a modification that decreases the mRNA level of the Slmyc2 gene, a modification that decreases the level of the SlMYC2 protein and/or a modification that decreases the activity of the SlMYC2 protein, as compared to the wild type Slmyc2 gene of SEQ ID No. 5.

Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.